查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2086258

醫藥中間體市場：2026-2032年全球市場預測（依中間體類型、生產製程、化學分類、劑型、純度、適應症及最終用戶分類）

Pharmaceutical Intermediates Market by Intermediate Type, Process Type, Chemical Class, Form, Purity Level, Indication, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，醫藥中間體市場將成長至 684.2 億美元，複合年成長率為 8.66%。

主要市場統計數據
基準年 2025 382.3億美元
預計年份：2026年 414.4億美元
預測年份 2032 684.2億美元
複合年成長率 (%) 8.66%

醫藥中間體是用於生產活性藥物成分（API）、學名藥、生物製藥生產試劑以及高附加價值原料藥的化學成分明確的成分。全球學名藥的擴張、慢性病盛行率的上升、癌症和代謝疾病治療藥物研發管線的加速推進，以及對符合現行藥品生產品質管理規範（GMP）要求的穩健的API供應鏈的需求，共同推動了醫藥中間體的需求成長。

世界衛生組織 (WHO)、美國食品藥物管理局(FDA)、歐洲藥品管理局 (EMA)、經濟合作暨發展組織(OECD)、世界貿易組織 (WTO) 和聯合國商品貿易統計資料庫 (UN Comtrade) 等機構提供的公共衛生、監管和貿易數據，持續顯示醫藥生產生態系統高度互聯互通。在這種環境下，買家優先考慮具備卓越雜質控制、文件完整性、可追溯性、環境合規性和可擴展化學合成能力的認證供應商。因此，醫藥中間體市場正從成本主導採購轉向風險管理和品質主導採購。

醫藥中間體供應的變革性變化

供應鏈多元化、監管力度加大以及化學製程日益複雜，正在重塑醫藥中間體的模式。製造商正投資於連續生產流程、高活性物質密閉控制、綠色化學以及先進的分析檢測技術，以降低批次間差異，並提高對ICH、FDA、EMA和藥典要求的合規性。

人工智慧（AI）的累積影響

人工智慧（AI）整體成為推動藥物中間體開發和生產的重要力量。 AI驅動的逆合成平台能夠幫助化學家識別可行的合成路線、比較原料的可用性、預測反應結果並縮短開發週期。機器學習模型也被應用於預測雜質、選擇溶劑、控制結晶、提高反應產率和最佳化製程。

對關鍵區域的洞察

亞太地區在醫藥中間體領域持續發揮核心作用。中國和印度擁有強大的化學合成能力、廣泛的原料網路和成熟的原料藥出口系統。日本、韓國、新加坡和澳洲則在高品質生產、先進製程開發以及符合監管市場要求方面具備優勢。該地區還能滿足客戶對環境審核、現代化品管以及更透明的供應商認證的需求，尤其是在受監管的醫藥供應鏈中使用的高純度中間體方面。

主要群體洞察

隨著新加坡、馬來西亞、泰國、越南和印尼等國吸引生命科學、特種化學品和區域分銷領域的投資，東協在醫藥中間體市場佔有日益重要的地位。儘管該地區受益於基礎設施的改善、貿易一體化以及接近性亞洲主要供應鏈的優勢，但監管協調、熟練勞動力保障以及完善一致的品管系統仍然是關鍵的發展挑戰。

主要國家的概況

美國是醫藥中間體的主要需求中心，這得益於大規模的處方藥市場、FDA嚴格的供應監管要求以及強大的創新生態系統。加拿大憑藉其規範的生產體系、生命科學研究以及通往北美貿易路線的便利，對美國市場起到了補充作用。墨西哥因其近岸外包、成本優勢和接近性美國買家的地理優勢而備受關注，而巴西則憑藉其大規模的公共和私人醫療保健市場以及成熟的學名藥消費體系，為拉丁美洲的需求提供了支持。

為行業領導者提供的實用建議

產業領導者應透過對各地區的二級供應商進行認證，減少對單一供應商的依賴。應優先考慮那些在監管檢查方面擁有良好記錄、具備雜質控制專業知識、檢驗的變更管理體係以及環境實踐透明的供應商。採購團隊應從以價格為導向的談判轉向風險調整型採購模式，該模式應考慮前置作業時間可靠性、文件品質、審計永續性績效和地緣政治風險等因素。

調查方法

本執行摘要基於二手研究和分析整合，利用了公開且業界認可的資訊來源，包括監管出版刊物、藥典標準、國際貿易數據、專利和臨床研發管線指標、公共衛生統計數據以及醫療保健需求趨勢。主要參考資料包括美國FDA、EMA、WHO、OECD、WTO、聯合國商品貿易統計資料庫（UN Comtrade）以及各國衛生部門的指導意見和市場訊號。

結論

醫藥中間體市場正步入一個更具策略性的階段，在這個階段，品質、韌性、監管信心和永續性與成本競爭力同等重要。儘管全球醫藥需求和學名藥市場滲透率的不斷提高持續支撐著採購活動，但不斷擴展的創新研發管線正在推動對特殊、高純度和難以合成的中間體的需求成長。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 醫藥中間體市場：依中間體類型分類

  • API 中級
    • 小分子API中間體
    • 生物製藥原料藥中間體
  • 原料藥的中間體

第8章 醫藥中間體市場：依製程類型分類

  • 生物技術合成
    • 發酵基地
    • 酵素催化法
    • 無細胞系統
  • 化學合成
    • 傳統間歇式合成
    • 連續流合成
    • 催化合成

第9章 醫藥中間體市場：依化學分類

  • 鹵化合物
  • 雜環化合物
  • 有機金屬化合物
  • 胜肽中間體
  • 碳水化合物中間體
  • 核苷和核苷酸中間體

第10章 醫藥中間體市場：依劑型分類

  • 固體中間體
    • 粉末
    • 水晶
    • 顆粒
  • 液體中間體
    • 解決方案
    • 暫停
  • 半固體中間體

第11章 醫藥中間體市場：依純度分類

  • 技術級
  • 醫藥級

第12章：醫藥中間體市場：依適應症分類

  • 抗糖尿病藥物
  • 感染疾病物
    • 抗生素
    • 抗病毒藥物
    • 抗真菌藥物
  • 心血管系統
  • 中樞神經系統
  • 腫瘤學

第13章 醫藥中間體市場：依最終用戶分類

  • 契約製造組織
  • 製藥公司
  • 研究機構

第14章 醫藥中間體市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第15章 醫藥中間體市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 醫藥中間體市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第18章：公司簡介

  • Lonza Group AG
  • Wuxi AppTec Co., Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Evonik Industries AG
  • Divi's Laboratories Limited
  • Aarti Industries Limited
  • Sun Pharmaceutical Industries Limited
  • Sanofi SA
  • Sumitomo Chemical Co., Ltd.
  • Pfizer Inc.
  • Albemarle Corporation
  • Cambrex Corporation
  • BASF SE
  • Arkema SA
  • Johnson Matthey PLC
  • AR Life Sciences Pvt. Ltd.
  • ACTYLIS
  • Curia Global, Inc.
  • EUROAPI SA
  • Hikal Limited
  • Hubei Biocause Pharmaceutical Co., Ltd.
  • Jubilant Ingrevia Limited
  • Lianhe Aigen Pharma Co., Ltd.
  • Midas Pharma GmbH
  • SimSon Pharma Limited
  • Zhejiang Huahai Pharmaceutical Co., Ltd.
  • Zhejiang Medicine Co., Ltd.
  • Zhejiang NHU Co., Ltd.
Product Code: MRR-030EE48515E9

The Pharmaceutical Intermediates Market is projected to grow by USD 68.42 billion at a CAGR of 8.66% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 38.23 billion
Estimated Year [2026] USD 41.44 billion
Forecast Year [2032] USD 68.42 billion
CAGR (%) 8.66%

Pharmaceutical intermediates are chemically defined building blocks used to manufacture active pharmaceutical ingredients (APIs), specialty generics, biologics-enabling reagents, and high-value drug substances. Demand is being shaped by the global expansion of generic medicines, rising chronic disease prevalence, accelerated oncology and metabolic disorder pipelines, and the need for resilient API supply chains that meet current Good Manufacturing Practice expectations.

Public health, regulatory, and trade data from organizations such as the World Health Organization, U.S. FDA, European Medicines Agency, OECD, WTO, and UN Comtrade consistently point to a highly interconnected pharmaceutical manufacturing ecosystem. In this environment, buyers are prioritizing qualified suppliers with strong impurity control, documentation integrity, traceability, environmental compliance, and scalable chemistry capabilities. The pharmaceutical intermediates market is therefore moving beyond cost-led sourcing toward risk-managed, quality-led procurement.

Transformative Shifts in Pharmaceutical Intermediate Supply

The pharmaceutical intermediates landscape is being reshaped by supply chain diversification, tighter regulatory scrutiny, and a shift toward complex chemistry. Manufacturers are investing in continuous processing, high-potency containment, green chemistry, and advanced analytical testing to reduce batch variability and improve compliance with ICH, FDA, EMA, and pharmacopeial expectations.

Another structural shift is the growing preference for dual sourcing and regionalized production. The COVID-19 pandemic, geopolitical tensions, export controls, energy-price volatility, and logistics disruptions exposed vulnerabilities in concentrated supply chains. As a result, pharmaceutical companies are increasingly evaluating total cost of ownership, regulatory reliability, environmental performance, data integrity, and security of supply when selecting intermediate suppliers.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a practical accelerator across pharmaceutical intermediate development and manufacturing. AI-enabled retrosynthesis platforms help chemists identify feasible routes, compare raw material availability, predict reaction outcomes, and reduce development timelines. Machine learning models are also being applied to impurity prediction, solvent selection, crystallization control, reaction yield improvement, and process optimization.

In manufacturing, AI supports predictive maintenance, real-time quality monitoring, deviation detection, digital batch record review, and early warning systems for process drift. These applications align with regulatory interest in advanced manufacturing, quality-by-design principles, and lifecycle process verification. While AI does not replace validated experimentation, it strengthens data-driven decision-making and can reduce rework, waste, and scale-up risk when integrated with robust laboratory and plant data governance.

Key Regional Insights

Asia-Pacific remains central to pharmaceutical intermediates because China and India host extensive chemical synthesis capacity, broad raw material networks, and established API export ecosystems. Japan, South Korea, Singapore, and Australia add high-quality manufacturing, advanced process development, and regulated-market capabilities. The region is also responding to environmental inspections, quality modernization, and customer demand for more transparent supplier qualification, especially for high-purity intermediates used in regulated pharmaceutical supply chains.

North America is strengthening its role through reshoring incentives, biologics-adjacent chemistry, specialty intermediates, and secure supply initiatives. The United States and Canada emphasize FDA-compliant manufacturing, advanced analytics, and high-value contract development and manufacturing services. Latin America, led by Brazil and Mexico, is gaining relevance as a nearshoring and regional access platform, supported by expanding healthcare demand, established generics consumption, and trade links with North America.

Europe remains a benchmark for regulated pharmaceutical production, with Germany, France, Italy, Spain, and the United Kingdom supporting specialty chemistry, compliance, and sustainable manufacturing. The Middle East is investing in pharmaceutical localization through Gulf industrial strategies, healthcare security programs, and industrial diversification. Africa is gradually building regional medicine production capacity through public health priorities, African Continental Free Trade Area momentum, and partnerships aimed at reducing import dependency for essential medicines and pharmaceutical inputs.

Key Group Insights

ASEAN is becoming more relevant for pharmaceutical intermediates as Singapore, Malaysia, Thailand, Vietnam, and Indonesia attract investment in life sciences, specialty chemicals, and regional distribution. The bloc benefits from improving infrastructure, trade integration, and proximity to major Asian supply chains, although regulatory harmonization, skilled workforce depth, and consistent quality system maturity remain important development areas.

The GCC is positioning pharmaceutical manufacturing as part of broader economic diversification. Saudi Arabia and the United Arab Emirates are emphasizing local production, healthcare security, and industrial clusters that can support formulation and selected intermediate capabilities. The European Union continues to set a high bar for quality, environmental control, traceability, and supply chain transparency, making it a preferred region for complex, regulated, and sustainability-sensitive intermediates.

BRICS countries collectively influence demand, production, and raw material flows through large populations, expanding healthcare systems, and significant chemical manufacturing capacity. G7 markets drive premium demand through innovation-led pipelines, strict regulatory expectations, mature reimbursement systems, and high-value outsourcing. NATO economies, while not a pharmaceutical trade bloc, are increasingly aligned around supply chain resilience for critical medicines, strategic health security, and reduced dependence on vulnerable sourcing routes.

Key Country Insights

The United States is a leading demand center for pharmaceutical intermediates because of its large prescription drug market, FDA-regulated supply requirements, and strong innovation ecosystem. Canada complements this position with regulated manufacturing, life sciences research, and access to North American trade routes. Mexico is gaining attention for nearshoring, cost-competitive manufacturing, and proximity to U.S. buyers, while Brazil anchors Latin American demand through its large public and private healthcare markets and established generics consumption.

In Europe, the United Kingdom supports drug discovery, specialty development, and contract manufacturing; Germany is recognized for fine chemicals, engineering, and process excellence; France maintains strong pharmaceutical production and regulatory sophistication; Italy and Spain contribute important API, generic, and contract manufacturing capacity; and Russia continues to prioritize domestic medicine security despite trade and sanctions-related constraints that affect equipment, technology, and cross-border procurement.

China remains a major global supplier of chemical intermediates and APIs, supported by scale, raw material integration, and extensive synthesis capabilities. India is a key generic-drug and API hub with growing investment in production-linked incentives and regulated-market compliance. Japan and South Korea focus on high-quality, technology-intensive intermediates and advanced pharmaceutical manufacturing, while Australia offers regulated-market credibility, clinical research links, and regional supply diversification for Asia-Pacific buyers.

Actionable Recommendations for Industry Leaders

Industry leaders should reduce single-source exposure by qualifying secondary suppliers across regions, prioritizing vendors with strong regulatory inspection histories, impurity expertise, validated change-control systems, and transparent environmental practices. Procurement teams should move from price-only negotiations to risk-adjusted sourcing models that include lead-time reliability, documentation quality, audit readiness, sustainability performance, and geopolitical exposure.

Manufacturers should invest in continuous manufacturing, process analytical technology, solvent recovery, waste reduction, high-potency handling, and digital quality systems. Commercial teams should align intermediate portfolios with high-demand therapeutic areas such as oncology, diabetes, cardiovascular disease, anti-infectives, and central nervous system therapies. Leaders should also formalize AI governance so that digital route design, predictive quality, and process optimization tools are auditable, secure, scientifically validated, and compatible with regulatory expectations.

Research Methodology

This executive summary is based on secondary research and analytical synthesis using publicly available and industry-recognized sources, including regulatory agency publications, pharmacopeial standards, international trade data, patent and clinical pipeline indicators, public health statistics, and healthcare demand trends. Key reference points include guidance and market signals from the U.S. FDA, EMA, WHO, OECD, WTO, UN Comtrade, and national health authorities.

The methodology emphasizes triangulation across demand drivers, manufacturing capacity, regulatory policy, supplier concentration, trade flows, quality requirements, sustainability priorities, and technology adoption. Insights were evaluated for consistency, credibility, and relevance to pharmaceutical intermediates, API supply chains, contract development and manufacturing, specialty chemicals, and regulated-market procurement, while avoiding unverified market sizing or forecasting claims.

Conclusion

The pharmaceutical intermediates market is entering a more strategic phase in which quality, resilience, regulatory confidence, and sustainability are as important as cost competitiveness. Global medicine demand and expanding generic penetration continue to support procurement activity, while innovation pipelines increase the need for specialized, high-purity, and difficult-to-synthesize intermediates.

Organizations that combine diversified sourcing, advanced chemistry, AI-enabled development, and strong compliance systems will be best positioned to capture value. As supply chains regionalize and customers demand greater transparency, pharmaceutical intermediate suppliers that demonstrate reliability, documentation integrity, responsible manufacturing, and scalable innovation will gain a durable competitive advantage.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Pharmaceutical Intermediates Market, by Intermediate Type

  • 7.1. API Intermediates
    • 7.1.1. Small Molecule API Intermediates
    • 7.1.2. Biologic API Intermediates
  • 7.2. Bulk Drug Intermediates

8. Pharmaceutical Intermediates Market, by Process Type

  • 8.1. Biotechnological Synthesis
    • 8.1.1. Fermentation Based
    • 8.1.2. Enzyme Catalyzed
    • 8.1.3. Cell Free Systems
  • 8.2. Chemical Synthesis
    • 8.2.1. Traditional Batch Synthesis
    • 8.2.2. Continuous Flow Synthesis
    • 8.2.3. Catalytic Synthesis

9. Pharmaceutical Intermediates Market, by Chemical Class

  • 9.1. Halogenated Compounds
  • 9.2. Heterocyclic Compounds
  • 9.3. Organometallic Compounds
  • 9.4. Peptide Intermediates
  • 9.5. Carbohydrate Intermediates
  • 9.6. Nucleoside And Nucleotide Intermediates

10. Pharmaceutical Intermediates Market, by Form

  • 10.1. Solid Intermediates
    • 10.1.1. Powders
    • 10.1.2. Crystals
    • 10.1.3. Granules
  • 10.2. Liquid Intermediates
    • 10.2.1. Solutions
    • 10.2.2. Suspensions
  • 10.3. Semi Solid Intermediates

11. Pharmaceutical Intermediates Market, by Purity Level

  • 11.1. Technical Grade
  • 11.2. Pharmaceutical Grade

12. Pharmaceutical Intermediates Market, by Indication

  • 12.1. Anti Diabetic
  • 12.2. Anti Infective
    • 12.2.1. Antibiotics
    • 12.2.2. Antivirals
    • 12.2.3. Antifungals
  • 12.3. Cardiovascular
  • 12.4. Central Nervous System
  • 12.5. Oncology

13. Pharmaceutical Intermediates Market, by End User

  • 13.1. Contract Manufacturing Organizations
  • 13.2. Pharmaceutical Companies
  • 13.3. Research Organizations

14. Pharmaceutical Intermediates Market, by Region

  • 14.1. Asia-Pacific
  • 14.2. North America
  • 14.3. Latin America
  • 14.4. Europe
  • 14.5. Middle East
  • 14.6. Africa

15. Pharmaceutical Intermediates Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Pharmaceutical Intermediates Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025

18. Company Profiles

  • 18.1. Lonza Group AG
  • 18.2. Wuxi AppTec Co., Ltd.
  • 18.3. Teva Pharmaceutical Industries Ltd.
  • 18.4. Evonik Industries AG
  • 18.5. Divi's Laboratories Limited
  • 18.6. Aarti Industries Limited
  • 18.7. Sun Pharmaceutical Industries Limited
  • 18.8. Sanofi S.A.
  • 18.9. Sumitomo Chemical Co., Ltd.
  • 18.10. Pfizer Inc.
  • 18.11. Albemarle Corporation
  • 18.12. Cambrex Corporation
  • 18.13. BASF SE
  • 18.14. Arkema S.A.
  • 18.15. Johnson Matthey PLC
  • 18.16. A. R. Life Sciences Pvt. Ltd.
  • 18.17. ACTYLIS
  • 18.18. Curia Global, Inc.
  • 18.19. EUROAPI S.A.
  • 18.20. Hikal Limited
  • 18.21. Hubei Biocause Pharmaceutical Co., Ltd.
  • 18.22. Jubilant Ingrevia Limited
  • 18.23. Lianhe Aigen Pharma Co., Ltd.
  • 18.24. Midas Pharma GmbH
  • 18.25. SimSon Pharma Limited
  • 18.26. Zhejiang Huahai Pharmaceutical Co., Ltd.
  • 18.27. Zhejiang Medicine Co., Ltd.
  • 18.28. Zhejiang NHU Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PHARMACEUTICAL INTERMEDIATES MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL PHARMACEUTICAL INTERMEDIATES MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL PHARMACEUTICAL INTERMEDIATES MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL PHARMACEUTICAL INTERMEDIATES MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL PHARMACEUTICAL INTERMEDIATES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL PHARMACEUTICAL INTERMEDIATES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL PHARMACEUTICAL INTERMEDIATES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY INTERMEDIATE TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY INTERMEDIATE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY PROCESS TYPE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY PROCESS TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY CHEMICAL CLASS, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY CHEMICAL CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY FORM, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY PURITY LEVEL, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY PURITY LEVEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 27. GLOBAL PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PHARMACEUTICAL INTERMEDIATES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY INTERMEDIATE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL API INTERMEDIATES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL API INTERMEDIATES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL API INTERMEDIATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL SMALL MOLECULE API INTERMEDIATES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL SMALL MOLECULE API INTERMEDIATES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL SMALL MOLECULE API INTERMEDIATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BIOLOGIC API INTERMEDIATES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BIOLOGIC API INTERMEDIATES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BIOLOGIC API INTERMEDIATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BULK DRUG INTERMEDIATES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BULK DRUG INTERMEDIATES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BULK DRUG INTERMEDIATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY PROCESS TYPE, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BIOTECHNOLOGICAL SYNTHESIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BIOTECHNOLOGICAL SYNTHESIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BIOTECHNOLOGICAL SYNTHESIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL FERMENTATION BASED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL FERMENTATION BASED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL FERMENTATION BASED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ENZYME CATALYZED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ENZYME CATALYZED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ENZYME CATALYZED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CELL FREE SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CELL FREE SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CELL FREE SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CHEMICAL SYNTHESIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CHEMICAL SYNTHESIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CHEMICAL SYNTHESIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL TRADITIONAL BATCH SYNTHESIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL TRADITIONAL BATCH SYNTHESIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL TRADITIONAL BATCH SYNTHESIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CONTINUOUS FLOW SYNTHESIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CONTINUOUS FLOW SYNTHESIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CONTINUOUS FLOW SYNTHESIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CATALYTIC SYNTHESIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CATALYTIC SYNTHESIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CATALYTIC SYNTHESIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY CHEMICAL CLASS, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL HALOGENATED COMPOUNDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL HALOGENATED COMPOUNDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL HALOGENATED COMPOUNDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL HETEROCYCLIC COMPOUNDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL HETEROCYCLIC COMPOUNDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL HETEROCYCLIC COMPOUNDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ORGANOMETALLIC COMPOUNDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ORGANOMETALLIC COMPOUNDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ORGANOMETALLIC COMPOUNDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PEPTIDE INTERMEDIATES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PEPTIDE INTERMEDIATES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PEPTIDE INTERMEDIATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CARBOHYDRATE INTERMEDIATES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CARBOHYDRATE INTERMEDIATES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CARBOHYDRATE INTERMEDIATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL NUCLEOSIDE AND NUCLEOTIDE INTERMEDIATES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL NUCLEOSIDE AND NUCLEOTIDE INTERMEDIATES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL NUCLEOSIDE AND NUCLEOTIDE INTERMEDIATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL SOLID INTERMEDIATES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL SOLID INTERMEDIATES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL SOLID INTERMEDIATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL POWDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL POWDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL POWDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CRYSTALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CRYSTALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CRYSTALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL GRANULES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL GRANULES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL GRANULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL LIQUID INTERMEDIATES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL LIQUID INTERMEDIATES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL LIQUID INTERMEDIATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL SOLUTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL SOLUTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL SOLUTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL SUSPENSIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL SUSPENSIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL SUSPENSIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL SEMI SOLID INTERMEDIATES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL SEMI SOLID INTERMEDIATES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL SEMI SOLID INTERMEDIATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY PURITY LEVEL, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL TECHNICAL GRADE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL TECHNICAL GRADE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL TECHNICAL GRADE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL PHARMACEUTICAL GRADE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL PHARMACEUTICAL GRADE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL PHARMACEUTICAL GRADE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ANTI DIABETIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANTI DIABETIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ANTI DIABETIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANTI INFECTIVE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ANTI INFECTIVE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ANTI INFECTIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ANTIBIOTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANTIBIOTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANTIVIRALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL ANTIVIRALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL ANTIVIRALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ANTIFUNGALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ANTIFUNGALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL ANTIFUNGALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL CARDIOVASCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL CARDIOVASCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL CARDIOVASCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL CENTRAL NERVOUS SYSTEM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL CENTRAL NERVOUS SYSTEM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL CENTRAL NERVOUS SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL CONTRACT MANUFACTURING ORGANIZATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL CONTRACT MANUFACTURING ORGANIZATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL CONTRACT MANUFACTURING ORGANIZATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL RESEARCH ORGANIZATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL RESEARCH ORGANIZATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL RESEARCH ORGANIZATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC PHARMACEUTICAL INTERMEDIATES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY INTERMEDIATE TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY API INTERMEDIATES, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY PROCESS TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY BIOTECHNOLOGICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY CHEMICAL CLASS, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY SOLID INTERMEDIATES, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY LIQUID INTERMEDIATES, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY PURITY LEVEL, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY ANTI INFECTIVE, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA PHARMACEUTICAL INTERMEDIATES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY INTERMEDIATE TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY API INTERMEDIATES, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY PROCESS TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY BIOTECHNOLOGICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY CHEMICAL CLASS, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY SOLID INTERMEDIATES, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY LIQUID INTERMEDIATES, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY PURITY LEVEL, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY ANTI INFECTIVE, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA PHARMACEUTICAL INTERMEDIATES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY INTERMEDIATE TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY API INTERMEDIATES, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY PROCESS TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY BIOTECHNOLOGICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY CHEMICAL CLASS, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY SOLID INTERMEDIATES, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY LIQUID INTERMEDIATES, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY PURITY LEVEL, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY ANTI INFECTIVE, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE PHARMACEUTICAL INTERMEDIATES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY INTERMEDIATE TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY API INTERMEDIATES, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY PROCESS TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY BIOTECHNOLOGICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY CHEMICAL CLASS, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY SOLID INTERMEDIATES, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY LIQUID INTERMEDIATES, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY PURITY LEVEL, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY ANTI INFECTIVE, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST PHARMACEUTICAL INTERMEDIATES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 184. MIDDLE EAST PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY INTERMEDIATE TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY API INTERMEDIATES, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY PROCESS TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY BIOTECHNOLOGICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY CHEMICAL CLASS, 2018-2032 (USD MILLION)
  • TABLE 190. MIDDLE EAST PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY SOLID INTERMEDIATES, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY LIQUID INTERMEDIATES, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY PURITY LEVEL, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY ANTI INFECTIVE, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA PHARMACEUTICAL INTERMEDIATES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY INTERMEDIATE TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY API INTERMEDIATES, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY PROCESS TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY BIOTECHNOLOGICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 202. AFRICA PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY CHEMICAL CLASS, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY SOLID INTERMEDIATES, 2018-2032 (USD MILLION)
  • TABLE 206. AFRICA PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY LIQUID INTERMEDIATES, 2018-2032 (USD MILLION)
  • TABLE 207. AFRICA PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY PURITY LEVEL, 2018-2032 (USD MILLION)
  • TABLE 208. AFRICA PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 209. AFRICA PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY ANTI INFECTIVE, 2018-2032 (USD MILLION)
  • TABLE 210. AFRICA PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 211. GLOBAL PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 212. ASEAN PHARMACEUTICAL INTERMEDIATES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 213. ASEAN PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY INTERMEDIATE TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. ASEAN PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY API INTERMEDIATES, 2018-2032 (USD MILLION)
  • TABLE 215. ASEAN PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY PROCESS TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY BIOTECHNOLOGICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 217. ASEAN PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 218. ASEAN PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY CHEMICAL CLASS, 2018-2032 (USD MILLION)
  • TABLE 219. ASEAN PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 220. ASEAN PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY SOLID INTERMEDIATES, 2018-2032 (USD MILLION)
  • TABLE 221. ASEAN PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY LIQUID INTERMEDIATES, 2018-2032 (USD MILLION)
  • TABLE 222. ASEAN PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY PURITY LEVEL, 2018-2032 (USD MILLION)
  • TABLE 223. ASEAN PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 224. ASEAN PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY ANTI INFECTIVE, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 226. GCC PHARMACEUTICAL INTERMEDIATES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 227. GCC PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY INTERMEDIATE TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. GCC PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY API INTERMEDIATES, 2018-2032 (USD MILLION)
  • TABLE 229. GCC PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY PROCESS TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. GCC PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY BIOTECHNOLOGICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 231. GCC PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 232. GCC PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY CHEMICAL CLASS, 2018-2032 (USD MILLION)
  • TABLE 233. GCC PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 234. GCC PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY SOLID INTERMEDIATES, 2018-2032 (USD MILLION)
  • TABLE 235. GCC PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY LIQUID INTERMEDIATES, 2018-2032 (USD MILLION)
  • TABLE 236. GCC PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY PURITY LEVEL, 2018-2032 (USD MILLION)
  • TABLE 237. GCC PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 238. GCC PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY ANTI INFECTIVE, 2018-2032 (USD MILLION)
  • TABLE 239. GCC PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPEAN UNION PHARMACEUTICAL INTERMEDIATES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPEAN UNION PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY INTERMEDIATE TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPEAN UNION PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY API INTERMEDIATES, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY PROCESS TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPEAN UNION PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY BIOTECHNOLOGICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPEAN UNION PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY CHEMICAL CLASS, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPEAN UNION PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPEAN UNION PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY SOLID INTERMEDIATES, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPEAN UNION PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY LIQUID INTERMEDIATES, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPEAN UNION PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY PURITY LEVEL, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPEAN UNION PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY ANTI INFECTIVE, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 254. BRICS PHARMACEUTICAL INTERMEDIATES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 255. BRICS PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY INTERMEDIATE TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. BRICS PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY API INTERMEDIATES, 2018-2032 (USD MILLION)
  • TABLE 257. BRICS PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY PROCESS TYPE, 2018-2032 (USD MILLION)
  • TABLE 258. BRICS PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY BIOTECHNOLOGICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 259. BRICS PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 260. BRICS PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY CHEMICAL CLASS, 2018-2032 (USD MILLION)
  • TABLE 261. BRICS PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 262. BRICS PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY SOLID INTERMEDIATES, 2018-2032 (USD MILLION)
  • TABLE 263. BRICS PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY LIQUID INTERMEDIATES, 2018-2032 (USD MILLION)
  • TABLE 264. BRICS PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY PURITY LEVEL, 2018-2032 (USD MILLION)
  • TABLE 265. BRICS PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 266. BRICS PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY ANTI INFECTIVE, 2018-2032 (USD MILLION)
  • TABLE 267. BRICS PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 268. G7 PHARMACEUTICAL INTERMEDIATES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 269. G7 PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY INTERMEDIATE TYPE, 2018-2032 (USD MILLION)
  • TABLE 270. G7 PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY API INTERMEDIATES, 2018-2032 (USD MILLION)
  • TABLE 271. G7 PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY PROCESS TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. G7 PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY BIOTECHNOLOGICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 273. G7 PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 274. G7 PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY CHEMICAL CLASS, 2018-2032 (USD MILLION)
  • TABLE 275. G7 PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 276. G7 PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY SOLID INTERMEDIATES, 2018-2032 (USD MILLION)
  • TABLE 277. G7 PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY LIQUID INTERMEDIATES, 2018-2032 (USD MILLION)
  • TABLE 278. G7 PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY PURITY LEVEL, 2018-2032 (USD MILLION)
  • TABLE 279. G7 PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 280. G7 PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY ANTI INFECTIVE, 2018-2032 (USD MILLION)
  • TABLE 281. G7 PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 282. NATO PHARMACEUTICAL INTERMEDIATES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 283. NATO PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY INTERMEDIATE TYPE, 2018-2032 (USD MILLION)
  • TABLE 284. NATO PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY API INTERMEDIATES, 2018-2032 (USD MILLION)
  • TABLE 285. NATO PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY PROCESS TYPE, 2018-2032 (USD MILLION)
  • TABLE 286. NATO PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY BIOTECHNOLOGICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 287. NATO PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 288. NATO PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY CHEMICAL CLASS, 2018-2032 (USD MILLION)
  • TABLE 289. NATO PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 290. NATO PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY SOLID INTERMEDIATES, 2018-2032 (USD MILLION)
  • TABLE 291. NATO PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY LIQUID INTERMEDIATES, 2018-2032 (USD MILLION)
  • TABLE 292. NATO PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY PURITY LEVEL, 2018-2032 (USD MILLION)
  • TABLE 293. NATO PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 294. NATO PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY ANTI INFECTIVE, 2018-2032 (USD MILLION)
  • TABLE 295. NATO PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 296. GLOBAL PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 297. UNITED STATES PHARMACEUTICAL INTERMEDIATES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 298. UNITED STATES PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY INTERMEDIATE TYPE, 2018-2032 (USD MILLION)
  • TABLE 299. UNITED STATES PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY API INTERMEDIATES, 2018-2032 (USD MILLION)
  • TABLE 300. UNITED STATES PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY PROCESS TYPE, 2018-2032 (USD MILLION)
  • TABLE 301. UNITED STATES PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY BIOTECHNOLOGICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 302. UNITED STATES PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 303. UNITED STATES PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY CHEMICAL CLASS, 2018-2032 (USD MILLION)
  • TABLE 304. UNITED STATES PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 305. UNITED STATES PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY SOLID INTERMEDIATES, 2018-2032 (USD MILLION)
  • TABLE 306. UNITED STATES PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY LIQUID INTERMEDIATES, 2018-2032 (USD MILLION)
  • TABLE 307. UNITED STATES PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY PURITY LEVEL, 2018-2032 (USD MILLION)
  • TABLE 308. UNITED STATES PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 309. UNITED STATES PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY ANTI INFECTIVE, 2018-2032 (USD MILLION)
  • TABLE 310. UNITED STATES PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 311. CANADA PHARMACEUTICAL INTERMEDIATES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 312. CANADA PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY INTERMEDIATE TYPE, 2018-2032 (USD MILLION)
  • TABLE 313. CANADA PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY API INTERMEDIATES, 2018-2032 (USD MILLION)
  • TABLE 314. CANADA PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY PROCESS TYPE, 2018-2032 (USD MILLION)
  • TABLE 315. CANADA PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY BIOTECHNOLOGICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 316. CANADA PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 317. CANADA PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY CHEMICAL CLASS, 2018-2032 (USD MILLION)
  • TABLE 318. CANADA PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 319. CANADA PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY SOLID INTERMEDIATES, 2018-2032 (USD MILLION)
  • TABLE 320. CANADA PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY LIQUID INTERMEDIATES, 2018-2032 (USD MILLION)
  • TABLE 321. CANADA PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY PURITY LEVEL, 2018-2032 (USD MILLION)
  • TABLE 322. CANADA PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 323. CANADA PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY ANTI INFECTIVE, 2018-2032 (USD MILLION)
  • TABLE 324. CANADA PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 325. MEXICO PHARMACEUTICAL INTERMEDIATES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 326. MEXICO PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY INTERMEDIATE TYPE, 2018-2032 (USD MILLION)
  • TABLE 327. MEXICO PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY API INTERMEDIATES, 2018-2032 (USD MILLION)
  • TABLE 328. MEXICO PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY PROCESS TYPE, 2018-2032 (USD MILLION)
  • TABLE 329. MEXICO PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY BIOTECHNOLOGICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 330. MEXICO PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 331. MEXICO PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY CHEMICAL CLASS, 2018-2032 (USD MILLION)
  • TABLE 332. MEXICO PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 333. MEXICO PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY SOLID INTERMEDIATES, 2018-2032 (USD MILLION)
  • TABLE 334. MEXICO PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY LIQUID INTERMEDIATES, 2018-2032 (USD MILLION)
  • TABLE 335. MEXICO PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY PURITY LEVEL, 2018-2032 (USD MILLION)
  • TABLE 336. MEXICO PHARMACEUTICAL INTERMEDIATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 337. MEXICO PHARMACEUTICAL INTERMEDIATES MAR